Millions of COVID-19 vaccine doses heading for landfill
Millions of doses of Novavax’s COVID-19 vaccine appear headed for landfill as their expiry date approaches. Only 220,000 doses of Nuvaxovid have been administered so…
Tag: Infectious diseases – Immunisation
GPs can order the bivalent COVID-19 vax from October – but don’t rush
The new bivalent COVID-19 vaccine will be available from 10 October, but GPs should refrain from ordering stocks until they run out of the original…
TGA signs off on first COVID-19 booster vaccine for 5-11-year-olds
The TGA has granted provisional approval to Australia’s first COVID-19 booster for kids aged 5-11. Pfizer’s paediatric Comirnaty vaccine received the TGA nod on…
There’s a new Omicron subvariant spreading – everything we know about BA.4.6
BA.4.6, a subvariant of the Omicron COVID-19 variant which has been quickly gaining traction in the US, is now confirmed to be spreading in the…
A GP guide to respiratory syncytial virus
Respiratory syncytial virus is a single-stranded RNA virus which causes infection of the respiratory tract. Discovered in 1956, it is one of the most common…
Original Moderna vax to be phased out for bivalent shot: Butler
The original Moderna COVID-19 vaccine will soon be phased out and replaced with the company’s new bivalent vaccine following ATAGI advice, the Federal Government says.…
5 worrying virus families that could cause the next pandemic
The Commonwealth Scientific and Industrial Research Organisation has delivered a comprehensive report on how we should prepare for future pandemics. The report identifies six key…
Monkeypox vax protection may be low, researchers warn
Their study measuring immune response to the vaccine may challenge the dose-sparing strategy.
Better COVID-19 vaccines are on the way – what do they do?
Regulators in Australia last week approved Omicron-specific boosters, following approval in the UK in mid-August. In Australia, a Moderna Omicron booster has been provisionally approved…
Universal RSV ‘immunisation’ on the horizon for infants
As drug manufacturers race to bring a vaccine to market, a monoclonal antibody appears poised for regulatory consideration.
